Third Quarter 2026
Filed Nov 4, 2026Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency)
Revenue grew 19.2%, or 19.6% in constant currency, with total Omnipod revenue up 19.7%, operating margin expanding 590 basis points, adjusted EPS rising 59.9%, and full-year constant-currency revenue guidance maintained to increased by segment.
Actuals vs. the company’s prior outlook
from its previous release| Metric | Guided | Reported | Verdict |
|---|---|---|---|
| Revenue growth in constant currency, Q3 | 17.5% - 19.5% in constant currency | 19.6% in constant currency | above |
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 revenueGAAP | $842M | – | 19.2% |
| Q3 2026 revenue growthnon-GAAP | 19.6% in constant currency | – | 19.6% in constant currency |
| Nine months ended September 30, 2026 revenueGAAP | $2.41B | – | 25.0% |
| Nine months ended September 30, 2026 revenue growthnon-GAAP | 23.8% in constant currency | – | 23.8% in constant currency |
| Q3 2026 cost of revenueGAAP | $209.9M | – | – |
| Q3 2026 gross profitGAAP | $632.1M | – | – |
| Q3 2026 gross marginGAAP | 75.1% | – | – |
| Q3 2026 adjusted gross profitnon-GAAP | $624.9M | – | – |
| Q3 2026 adjusted gross marginnon-GAAP | 74.2% | – | – |
| Q3 2026 research and development expensesGAAP | $91.6M | – | – |
| Q3 2026 selling, general and administrative expensesGAAP | $350.7M | – | – |
| Q3 2026 operating incomeGAAP | $189.8M | – | – |
| Q3 2026 operating marginGAAP | 22.5% of revenue | – | up 590 basis points over prior year |
| Q3 2026 adjusted operating incomenon-GAAP | $185.2M | – | – |
| Q3 2026 adjusted operating marginnon-GAAP | 22.0% of revenue | – | up 490 basis points compared to prior year |
| Q3 2026 interest expense, netGAAP | −$12.1M | – | – |
| Q3 2026 loss on extinguishment of debtGAAP | −$300K | – | – |
| Q3 2026 income before income taxesGAAP | $177.2M | – | – |
| Q3 2026 income tax expenseGAAP | −$36.1M | – | – |
| Q3 2026 effective tax rateGAAP | 20.4% | – | – |
| Q3 2026 net incomeGAAP | $141.1M | – | – |
| Q3 2026 diluted earnings per shareGAAP | $2.03 | – | – |
| Q3 2026 adjusted net incomenon-GAAP | $138M | – | 57.2% |
| Q3 2026 adjusted diluted earnings per sharenon-GAAP | $1.99 | – | 59.9% |
| Q3 2026 adjusted EBITDAnon-GAAP | $233.7M | – | – |
| Q3 2026 adjusted EBITDA marginnon-GAAP | 27.7% | – | – |
| Nine months ended September 30, 2026 gross profitGAAP | $1.72B | – | – |
| Nine months ended September 30, 2026 operating incomeGAAP | $441.5M | – | – |
| Nine months ended September 30, 2026 operating marginGAAP | 18.4% | – | – |
| Nine months ended September 30, 2026 net incomeGAAP | $327.1M | – | – |
| Nine months ended September 30, 2026 diluted earnings per shareGAAP | $4.69 | – | – |
| Nine months ended September 30, 2026 adjusted operating incomenon-GAAP | $473.2M | – | – |
| Nine months ended September 30, 2026 adjusted operating marginnon-GAAP | 19.7% | – | – |
| Nine months ended September 30, 2026 adjusted net incomenon-GAAP | $352.8M | – | – |
| Nine months ended September 30, 2026 adjusted diluted earnings per sharenon-GAAP | $5.06 | – | – |
| Nine months ended September 30, 2026 adjusted EBITDAnon-GAAP | $615.1M | – | – |
| Nine months ended September 30, 2026 free cash flownon-GAAP | $211.7M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. OmnipodThe Company completed its U.S. sales force expansion and continued its Type 2 action plan through onboarding and customer-support improvements, enhanced sampling, and sales-force compensation aligned with new customer start and retention goals. | $570.4M | – | 14.7% |
| International OmnipodThe Company expanded Abbott’s FreeStyle Libre 3 Plus CGM integration across Belgium, Netherlands, UK, Italy, Finland, Norway, Sweden, Australia, Switzerland and Germany. | $266.2M | – | 31.7%, or 33.0% in constant currency |
| Total Omnipod ProductsOmnipod represented the principal contributor to total revenue growth. | $836.6M | – | 19.7%, or 20.0% in constant currency |
| Drug DeliveryNo specific quarterly revenue driver was disclosed. | $5.5M | – | (22.7)% |
Year ending December 31, 2026 outlook
- RevenueTotal revenue growth: 22% - 23% GAAP; 21% - 22% constant currency
- NoteU.S. Omnipod revenue growth: 17.5% - 18.5% GAAP; 17.5% - 18.5% constant currency
- NoteInternational Omnipod revenue growth: 35% - 36% GAAP; 32% - 33% constant currency
- NoteTotal Omnipod revenue growth: 22.5% - 23.5% GAAP; 21.5% - 22.5% constant currency
- NoteDrug Delivery revenue growth: ~(40.0%) GAAP; ~(40%) constant currency
- NoteAdjusted Operating Margin: ~150 bps YoY expansion
- NoteAdjusted EPS Growth: >30%
Capital returns
- Received approval from the Board of Directors for a $1 billion share repurchase program.
- The Company expects to allocate approximately $400 million toward repurchases in the fourth quarter of 2026, funded with existing cash.
What drove it
- Total revenue increased 19.2%, or 19.6% in constant currency, and was slightly above the high end of the Company’s guidance range of 17.5% - 19.5% at constant currency rates.
- Total Omnipod revenue rose 19.7%, or 20.0% in constant currency, led by 31.7% International Omnipod growth and 14.7% U.S. Omnipod growth.
- The Company completed the full U.S. market release of Omnipod Discover, with adoption by more than 35,000 users and 5,000 healthcare professionals across available markets.
- The Company completed enrollment in the STRIVE2 type 1 diabetes cohort and the EVOLVE pivotal study.
- Q3 operating margin was 22.5%, up 590 basis points over prior year, while adjusted operating margin was 22.0%, up 490 basis points compared to prior year.
Concerns
- Drug Delivery revenue was $5.5 million and declined (22.7)%.
- Nine-month free cash flow was $211.7 million compared with $329.5 million in 2025, while capital expenditures were $(113.9) million compared with $(56.5) million in 2025.
- The Company cited risks including international regulatory, commercial and logistics risks, potential tariff expansion, dependence on a principal product platform, competitive products, manufacturing and supply-chain challenges, reimbursement risk, product safety issues, and cybersecurity risk.
- The Company reported voluntary medical device corrections issued in March and May 2026, reflected in adjustments to estimated warranty and related costs.
What to watch
- Execution of the Type 2 action plan, including new customer starts, retention, onboarding, sampling, and the completed U.S. sales-force expansion.
- Delivery against FY 2026 constant-currency guidance of 17.5% - 18.5% for U.S. Omnipod, 32% - 33% for International Omnipod, and 21% - 22% for total revenue.
- Whether adjusted operating margin achieves the guided ~150 bps YoY expansion.
- Execution of approximately $400 million of expected fourth-quarter 2026 share repurchases under the $1 billion authorization.
- Progress of the STRIVE2 and EVOLVE clinical trials supporting Omnipod 6 and fully closed-loop automated insulin delivery for adults with type 2 diabetes.
Balance sheet and cash flow
- Cash and cash equivalents were $584.4 million as of September 30, 2026, compared with $716.1 million as of December 31, 2025.
- Current portion of long-term debt was $19.1 million as of September 30, 2026, compared with $18.4 million as of December 31, 2025.
- Long-term debt, net was $943.0 million as of September 30, 2026, compared with $930.8 million as of December 31, 2025.
- Net cash provided by operating activities for the nine months ended September 30, 2026 was $325.7 million, compared with $386.0 million in 2025.
- Capital expenditures for the nine months ended September 30, 2026 were $(113.9) million, compared with $(56.5) million in 2025.
- Free cash flow for the nine months ended September 30, 2026 was $211.7 million, compared with $329.5 million in 2025.
- Accounts receivable, net was $689.0 million as of September 30, 2026, compared with $516.9 million as of December 31, 2025.
- Inventories were $552.1 million as of September 30, 2026, compared with $452.6 million as of December 31, 2025.
Analysis
Insulet reported a strong third quarter, with revenue of $842.0 million, up 19.2%, or 19.6% in constant currency. The result was slightly above the high end of the Company’s 17.5% - 19.5% constant-currency guidance range. Omnipod remained the revenue engine, contributing $836.6 million and growing 19.7%, or 20.0% in constant currency. International Omnipod revenue of $266.2 million grew 31.7%, or 33.0% in constant currency, materially faster than U.S. Omnipod revenue growth of 14.7% on $570.4 million of revenue. Drug Delivery revenue was $5.5 million and declined (22.7)%.
Profitability expanded sharply. GAAP gross margin was 75.1%, while GAAP operating income reached $189.8 million and operating margin was 22.5%, up 590 basis points over prior year. Adjusted operating income was $185.2 million and adjusted operating margin was 22.0%, up 490 basis points compared to prior year. GAAP net income was $141.1 million, or $2.03 per diluted share, versus $87.6 million, or $1.24 per diluted share. Adjusted net income was $138.0 million, up 57.2%, and adjusted diluted EPS was $1.99, up 59.9%.
The nine-month figures show continued revenue growth and earnings expansion, although cash conversion was lower than the prior-year period. Revenue was $2,405.4 million, up 25.0%, and adjusted EBITDA was $615.1 million, compared with $451.5 million. Net cash provided by operating activities was $325.7 million, compared with $386.0 million, while capital expenditures increased to $(113.9) million from $(56.5) million. As a result, free cash flow was $211.7 million versus $329.5 million. Cash and cash equivalents were $584.4 million, and long-term debt, net was $943.0 million, as of September 30, 2026.
Capital allocation shifted toward repurchases. The Board authorized a $1 billion share repurchase program, and the Company expects to allocate approximately $400 million toward fourth-quarter 2026 repurchases using existing cash. This follows a quarter in which the Company emphasized commercial execution in Type 2 diabetes, completed U.S. sales-force expansion, expanded Omnipod Discover, and broadened international CGM integration.
The full-year outlook calls for 21% - 22% constant-currency total revenue growth, with U.S. Omnipod growth of 17.5% - 18.5%, International Omnipod growth of 32% - 33%, and total Omnipod growth of 21.5% - 22.5%. Total revenue growth guidance is 22% - 23% on a GAAP basis. Management also expects approximately 150 basis points of adjusted operating-margin expansion and adjusted EPS growth of more than 30%. The guide preserves strong International Omnipod expectations and targets further profitability expansion while forecasting Drug Delivery revenue growth of approximately (40%).
Management, verbatim
Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion
Ashley McEvoy, President and CEO
We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation.
Ashley McEvoy, President and CEO
The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory.
Ashley McEvoy, President and CEO
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported Q3 metrics
- Q3 operating cash flow
- Q3 capital expenditures
- Q3 free cash flow
- Dividend declaration or dividend payment information
- Q3 GAAP gross-margin prior-year figure
- Q3 adjusted gross-profit and adjusted gross-margin prior-year figures
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.